Hunter Syndrome Treatment Market 2022 Size & Share | Market worth USD 1118.4 million with 6.0% CAGR by 2027

The global “Hunter Syndrome Treatment Market” is predicted to reach USD 1,118.4 million by 2026, exhibiting a CAGR of 6.0% during the forecast period. The increasing R&D investments by key players for the development of novel therapies to treat rare diseases in patients will be critical factor in boosting the Hunter syndrome treatment market growth during the forecast period. Moreover, the rising clinical studies for diabetes and coronary artery disease (CAD) will have a positive impact on market during the forecast period.

In addition, the surge in rare and genetic diseases will uplift the Hunter syndrome treatment market share. According to the Genetic and Rare Diseases Information Center (GARD), there can be an estimated 7,000 rare diseases and the total number of individuals in the U.S. from these rare diseases can be 25-30 million.

According to the report, published by Fortune Business Insights, tiled “Hunter Syndrome Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)/ Intrathecal), By End User (Hospitals, Specialty Clinics and Others), and Regional Forecast, 2019-2026” the market size stood at USD 702.4 million in 2018. The Hunter syndrome treatment market report focuses on demonstrating a complete assessment of the market. It contains facts, thoughtful insights, historical information, industry-validated market information, and projections with a suitable set of assumptions and methodology. It offers valuable insights into all the notable developments of the market. It is created after extensive research followed by an all-encompassing analysis to benefit companies, stakeholders, financers, and potential investors. Moreover, it also includes product launches, acquisitions, collaborations and partnerships, and industry developments.

Get Request a Sample Copy of the Hunter Syndrome Treatment Report:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hunter-syndrome-treatment-market-102536

What is the Scope of this market?
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

Geographical Analysis:
• North America (The U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• The Middle East & Africa (South Africa, GCC, and the Rest of the Middle East & Africa)

Major Hunter Syndrome Treatment Market Key players covered in the report include:
• Shire (Takeda Pharmaceutical Company Limited)
• Denali Therapeutics
• ArmaGen
• Inventiva
• Green Cross Corp. (GC Pharma)
• CANbridge Life Sciences Ltd.

Hunter Syndrome Treatment Market Analysis 2022:
Competitive Landscape:

Agreement between Clinigen K.K. and GC Pharma to Enable Growth

Clinigen K.K, a Japanese licensed medical supplier, and GC Pharma, a biopharmaceutical company announced a licensing agreement for the manufacturing and commercialization of Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome. The agreement between the two companies can be a critical factor in fostering the growth of the market owing to the methods to aid severe patients and therefore improve their condition. Furthermore, Hunterase ICV will be directly delivered to cerebral ventricles by intracerebroventricular (ICV) administration, in order to reach the cells of the brain and central nervous system. Furthermore, Yoshikazu Nakamura, Representative Director at Clinigen K.K, said “Hunter Syndrome is a complex disease with unmet medical need. We earnestly hope that this product provides significant benefit to patients in Japan.” In addition, President at GC Pharma, Eun Chul, said in statement, “we are delighted to further enhance the value of Hunterase through this partnership, our efforts to make substantial differences in the lives of those with Hunter syndrome in all markets will continue by providing new treatment environments and opportunities.”

For More Information :
https://www.fortunebusinessinsights.com/hunter-syndrome-treatment-market-102536

Competitive Landscape:

The market in North America generated a revenue of USD 358.9 million in 2018 and is predicted to grow rapidly during the forecast period. The growth in the region is attributed to the high diagnosis and treatment for rare diseases. The growing reimbursement policies for therapies will have a positive impact on the market in the region.

Asia Pacific is predicted to witness high growth rate in the forthcoming years owing to the developing healthcare infrastructure. Also, the presence of major players in the region will bolster healthy growth in Asia Pacific. In addition, ongoing clinical trials will boost the Hunter syndrome treatment market trends in the forthcoming years. For instance, the Phase 1/2 clinical trial conducted and initiated by Prof. Torayuki Okuyama in National Center for Child Health and Development in Japan showed a significant decrease in Heparan sulfate which causes mental retardation.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hunter-syndrome-treatment-market-102536

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
LinkedIn: https://www.linkedin.com/company/fortune-business-insights
Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd

This release was published on openPR.